to physiological and pathological alterations in coronary hemodynamics. Relief of AS by transcatheter aortic valve implantation (TAVI) decreases ventricular afterload and is expected to improve microvascular function immediately. We evaluated the effect of AS on coronary hemodynamics and the immediate effect of TAVI. Methods and Results-Intracoronary pressure and flow velocity were simultaneously assessed at rest and at maximal hyperemia in an unobstructed coronary artery in 27 patients with AS before and immediately after TAVI and in 28 patients without AS. Baseline flow velocity was higher and baseline microvascular resistance was lower in patients with AS as compared with controls, which remained unaltered post-TAVI. In patients with AS, hyperemic flow velocity was significantly lower as compared with controls (44.5±14.5 versus 54.3±18.6 cm/s; P=0.04). Hyperemic microvascular resistance (expressed in mm Hg·cm·s −1 ) was 2.10±0.69 in patients with AS as compared with 1.80±0.60 in controls (P=0.096). Coronary flow velocity reserve in patients with AS was lower, 1.9±0.5 versus 2.7±0.7 in controls (P<0.001). Improvement in coronary hemodynamics after TAVI was most pronounced in patients without post-TAVI aortic regurgitation. In these patients (n=20), hyperemic flow velocity increased significantly from 46.24±15.47 pre-TAVI to 56.56±17.44 cm/s post-TAVI (P=0.003). Hyperemic microvascular resistance decreased from 2.03±0.71 to 1.66±0.45 (P=0.050). Coronary flow velocity reserve increased significantly from 1.9±0.4 to 2.2±0.6 (P=0.009).
A ortic valve stenosis (AS) induces a compensatory increase in left ventricular mass to counteract the resistance to cardiac outflow induced by the reduction in valve area. 1 This compensatory change in the structure of the left ventricle leads to several physiological and pathological alterations in coronary and left ventricular hemodynamics, [2] [3] [4] which are associated with coronary microvascular dysfunction. It is hypothesized that the main contributors to coronary microvascular dysfunction are the increased hemodynamic load on the left ventricle, a reduction in diastolic perfusion time, and the absolute magnitude of aortic valve area. 5 Relief of AS by transcatheter aortic valve implantation (TAVI) induces an immediate decrease in ventricular afterload and would therefore be expected to provide an immediate and substantial improvement in coronary microvascular function. However, data on the effect of TAVI on coronary hemodynamics is limited, and available data on clinical coronary physiology is mainly related to the effects of long-term regression of left ventricular hypertrophy on coronary flow reserve. [5] [6] [7] [8] [9] [10] Simultaneous assessment of intracoronary pressure and flow using dual sensor-equipped guide wires allows the calculation of coronary flow reserve, as well as the selective evaluation of the coronary microcirculation by means of the microvascular resistance index, both of which are unequivocally related to myocardial ischemia and prognosis in patients with obstructive coronary artery disease. 11, 12 We sought to Impact of TAVI on Coronary Hemodynamics evaluate the effects of AS on coronary hemodynamics as compared with a cohort of patients without AS and to document the immediate effect of TAVI by means of comprehensive assessment of the coronary circulation using simultaneous invasive coronary pressure and flow velocity measurements.
Methods

Patient Population
A total of 55 patients were included in the study. Twenty-seven patients with AS and angiographically unobstructed left coronary artery were included. TAVI was indicated according to international recommendations. 13, 14 Exclusion criteria were any previous coronary intervention in the study vessel or severely impaired renal function. Twenty-eight patients without AS with an angiographically unobstructed left coronary artery who were scheduled for elective physiological assessment of epicardial disease severity formed the control group. Exclusion criteria for this control group were recent myocardial infarction (<6 weeks), prior cardiac surgery, hypertrophic cardiomyopathy, or severe heart failure. The institutional review committee approved the study protocol and all patients gave written informed consent.
Coronary Angiography and Physiological Measurements
Coronary angiography was performed according to standard practice. After diagnostic angiography, a dual sensor-equipped guidewire (ComboWire, Volcano Corp, San Diego) was used for simultaneous assessment of intracoronary pressure and flow velocity. Aortic pressure was concomitantly recorded through the guiding catheter. Measurements were acquired both during resting conditions, as well as during hyperemia, induced by an intracoronary bolus of adenosine (40-60μg) . In the control group, nitroglycerin (0.1 mg intracoronary) was administered before intracoronary measurements. For clinical reasons, nitroglycerin was not administered in the AS patients. In all patients with AS, measurements were performed during the TAVI procedure, immediately before and immediately after valve implantation, within a time frame of 15 minutes.
Aortic Valve Stenosis and Transcatheter Aortic Valve Implantation Procedure
Transthoracic echocardiography was performed before the TAVI procedure with a GE Vivid Dimension machine (GE Healthcare, Horten, Norway), all with 2D images, to assess the severity of valvular stenosis and left ventricular function. All views were obtained according to the recommendations of the American Society of Echocardiography. 15 The TAVI procedures were performed with either the selfexpandable Medtronic Corevalve bioprosthesis (Medtronic Inc, Minneapolis, MN) or the balloon expandable Edwards SAPIEN/SAPIEN XT bioprosthesis (Edwards Lifesciences LCC, Irvine, CA) at discretion of the operator. The procedures have been described in detail previously. 16, 17 Four of the TAVI procedures were performed under general anesthesia and 23 procedures were performed under mild systemic conscious sedation with local analgesia for percutaneous access. 18 Transthoracic echocardiography was repeated before hospital discharge (1-7 days after the procedure) to document the position and function of the implanted prosthesis.
Data Analysis
From the intracoronary pressure and flow signals, fractional flow reserve (FFR) was calculated as the ratio between mean distal coronary and mean aortic pressure during maximum hyperemia. Coronary flow reserve (CFR) was calculated as the ratio between coronary flow velocity at maximum hyperemia and coronary flow velocity at rest. The microvascular resistance index was defined as the ratio of mean distal coronary pressure to average peak flow velocity and was calculated both during baseline (baseline microvascular resistance) and peak hyperemia (hyperemic microvascular resistance). The ability of the resistance vessels to dilate under maximal hyperemic conditions (variable arteriolar resistance) was defined as the difference between baseline and hyperemic microvascular resistance 19 and was expressed both in absolute terms, as well as a percentage of baseline.
Statistical Analysis
Continuous variables are presented as mean and standard deviation (SD). Between the control and AS group, continuous variables were
WHAT IS KNOWN
• Aortic valve stenosis induces a compensatory increase in left ventricular mass, leading to physiological and pathological alterations in coronary and left ventricular hemodynamics.
• These alterations are associated with coronary microvascular dysfunction.
• Coronary microvascular dysfunction is associated with impaired clinical prognosis.
• Transcatheter aortic valve implantation immediately changes ventricular hemodynamics, potentially reversing coronary microvascular dysfunction.
WHAT THE STUDY ADDS
• Transcatheter aortic valve implantation immediately improves ventricular hemodynamics and partly relieves the pathological increase in minimal microvascular resistance.
• Transcatheter aortic valve implantation is associated with an improvement in coronary vasodilatory reserve.
• Autoregulatory microvascular tone, developed in response to the increase in ventricular mass, remains unaltered immediately after TAVI. Values are n (%) or mean±SD. ACE indicates angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; NYHA, New York Heart Association; MI, myocardial infarction; and PCI, percutaneous coronary intervention. Impact of TAVI on Coronary Hemodynamics compared using an unpaired Student's t test for different variances. Comparisons within the AS group before and after TAVI were performed with a paired Student's t test. Categorical variables are expressed as frequencies (percentages) and were compared between groups using the Fisher exact test, as appropriate. Analyses of intracoronary physiological parameters were primarily performed in those patients with optimal TAVI results, defined as absence of or trivialto-mild residual aortic regurgitation post-TAVI (less than grade 2), because suboptimal hemodynamic results after TAVI may interfere with the effect of TAVI on the coronary circulation in patients with AS. A P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL).
Results
Patient Population
The baseline characteristics of the overall patient population, as well as stratified by the presence of aortic stenosis, are presented in Table 1 . Patients with aortic valve stenosis were significantly older (82±8 years for AS patients versus 63±5 years in the control group, P<0.001) and were less likely to be male (P=0.013).
Effect of TAVI on Left Ventricular Hemodynamics
As measured by transthoracic echocardiography, the mean aortic valve area in the AS patients increased from 0.8±0.2 to 1.9±0.8 cm 2 (P<0.001). Mean and maximum aortic valve pressure gradient decreased from 67.3±16.9 to 17.8±8.4 mm Hg and 42.8±14.3 to 9.0±4.5 mm Hg, respectively (P<0.001; Table 2 ). Significant aortic regurgitation after TAVI (at least moderate) was present in 22% of patients (6 out of 27). In one patient, postprocedural aortic regurgitation was not assessed because of postprocedural complications, which was excluded from analyses across patients with optimal TAVI results. Consequently, the subgroup of patients with optimal TAVI results included 20 out of 27 patients (74%).
Heart rate of patients with AS pre-TAVI was equivalent as compared with control patients, both during baseline conditions and during hyperemia ( Table 3 ). In patients with AS, heart rate during baseline conditions increased slightly, although statistically significant, from 68±11 bpm pre-TAVI to 72±11 bpm post-TAVI (P=0.001). Similarly, heart rate during coronary hyperemia amounted to 70±12 bpm before TAVI versus 75±15 bpm after TAVI (P=0.006; Table 4 ). A similar trend in heart rate was observed in patients without pertinent aortic regurgitation post-TAVI (basal heart rate, 70±11 bpm pre-TAVI and 75±10 bpm post-TAVI [P=0.002]; hyperemic heart rate, 72±12 pre-TAVI to 77±16 bpm post-TAVI [P=0.004]; Table 5 ).
Effect of TAVI on Coronary Flow
Baseline flow velocity was higher in patients with AS before TAVI as compared with control patients (24.4±8.6 versus 20.7±7.8 cm/s, respectively; P=0.10; Table 3 ). TAVI did not materially alter baseline flow velocity in patients with AS (24.4±8.6 cm/s pre-TAVI versus 25.5±9.0 cm/s post-TAVI; P=0.401; Table 4 ). Similar, in patients with an optimal postprocedural result, baseline flow velocity remained unaltered after TAVI (25.6±8.9 cm/s pre-TAVI versus 26.8±9.6 cm/s post-TAVI; P=0.454; Table 5 ).
Hyperemic flow velocity was significantly lower in patients with AS before TAVI as compared with control patients (44.5±14.5 cm/s versus 54.3±18.6 cm/s, respectively; P=0.04; Table 3 ). In AS patients, TAVI yielded a significant increase in hyperemic flow velocity (from 44.5±14.5 cm/s to 51.1±18.1 cm/s; P=0.03). Consequently, hyperemic flow velocity in AS patients after TAVI was similar to reference values in the control group (P=0.535; Table 6 ). In patients without pertinent post-TAVI aortic regurgitation (less than moderate), hyperemic flow velocity increased from 46.2±15.5 cm/s before TAVI to 56.6±17.4 cm/s immediately after TAVI (P=0.003; Table 5 and Figure 1 ) and thereby reached values equivalent to those observed in control patients.
Patients with AS had a significantly lower pre-TAVI CFR as compared with patients without aortic valve stenosis (CFR in AS 1.9±0.5 versus CFR in controls 2.7±0.7; P<0.001). In AS patients, TAVI yielded a 10% increase in CFR, which did not reach formal statistical significance (from 1.9±0.5 pre-TAVI to 2.1±0.7 after TAVI; P=0.11). In patients without pertinent aortic regurgitation post-TAVI (less than moderate), a significant increase in CFR after TAVI was documented Values are mean±SD. APV indicates average peak flow velocity (cm/s); bMR, baseline microvascular resistance (mm Hg·cm·s −1 ); CFR, coronary flow reserve; hMR, hyperemic microvascular resistance (mm Hg·cm·s −1 ); HR, heart rate (bpm); Pa, aortic pressure (mm Hg); Pd, distal coronary pressure (mm Hg); VAR, variable arteriolar resistance; and VAR%, percentage variable arteriolar resistance. Impact of TAVI on Coronary Hemodynamics (CFR 1.9±0.4 pre-TAVI versus 2.2±0.6 post-TAVI; P=0.009; Figure 2 ). Hence, TAVI resulted in an increase in CFR toward reference values, but CFR remained substantially lower in AS patients, even in those patients in whom the acute procedural success was highest.
Effect of TAVI on Microvascular Resistance
Microvascular resistance during baseline conditions was significantly higher in the control group as compared with patients with AS before TAVI (5.28±2.02 mm Hg·cm·s −1 in the control group versus 4.16±1.48 mm Hg·cm·s −1 in patients with AS before TAVI, P=0.02). In AS patients, baseline microvascular resistance did not materially change immediately after TAVI (P=0.41). Similar findings were applied to patients without pertinent regurgitation (P=0.89).
Hyperemic microvascular resistance was 1.80±0.60 in the control group compared with 2.10±0.69 in patients with AS before TAVI (P=0.096). TAVI resulted in an immediate decrease in hyperemic microvascular resistance, which showed a strong trend toward statistical significance (2.10±0.69 mm Hg·cm·s −1 pre-TAVI versus 1.83±0.58 mm Hg·cm·s −1 post-TAVI, P=0.07). In patients without pertinent aortic regurgitation post-TAVI, hyperemic microvascular resistance was 2.03±0.71 mm Hg·cm·s −1 pre-TAVI, which decreased to 1.66±0.45 mm Hg·cm·s −1 immediately after TAVI (P=0.050; Figure 3 ).
The variable arteriolar resistance amounted to 3.48±1.70 mm Hg·cm·s −1 in the control group and to 2.06±1.22 mm Hg·cm·s −1 before TAVI, which improved to 2.13±1.05 mm Hg·cm·s −1 directly after TAVI. In patients without pertinent aortic regurgitation post-TAVI, variable arteriolar resistance pre-TAVI was 1.82±1.01 mm Hg·cm·s −1 pre-TAVI and improved to 2.20±1.02 mm Hg·cm·s −1 directly after TAVI (P=0.12). Hence, coronary vasodilation by intracoronary adenosine induced a 64% decrease in MR in the control group and a 47% decrease in the AS group before TAVI (P<0.0001) compared with a 51% decrease after TAVI. In patients without pertinent aortic regurgitation, post-TAVI percentage variable arteriolar resistance pre-TAVI was 46% pre-TAVI and improved significantly to 54% directly after TAVI (P=0.021).
Notably, in patients with AS, FFR amounted 0.97±0.05 before TAVI, which decreased significantly to 0.95±0.06 directly after TAVI (P=0.042).
Discussion
The present study, involving patients with angiographically unobstructed left coronary arteries, comprehensively documents the alterations in coronary hemodynamics associated with aortic valve stenosis and describes the immediate effects of TAVI on the coronary microvasculature and coronary flow by simultaneously assessed intracoronary pressure and flow velocity. Our result suggest that microvascular dysfunction in aortic valve stenosis patients originates from a combination of physiological compensatory vasodilation of the autoregulated microvasculature and a pathological increase in minimal microvascular resistance, resulting in a reduction of the vasodilatory reserve capacity of the coronary microcirculation and CFR. Moreover, it documents that TAVI induces an immediate decrease in hyperemic microvascular resistance and an immediate increase in hyperemic flow velocity, whereas resting hemodynamics remains unaltered. TAVI Values are mean±SD. APV indicates average peak flow velocity (cm/s); bMR, baseline microvascular resistance (mm Hg·cm·s −1 ); CFR, coronary flow reserve; hMR, hyperemic microvascular resistance (mm Hg·cm·s −1 ); HR, heart rate (bpm); Pa, aortic pressure (mm Hg); Pd, distal coronary pressure (mm Hg); VAR, variable arteriolar resistance; and VAR%, percentage variable arteriolar resistance. Values are mean±SD. APV indicates average peak flow velocity (cm/s); bMR, baseline microvascular resistance (mm Hg·cm·s −1 ); CFR, coronary flow reserve; hMR, hyperemic microvascular resistance (mm Hg·cm·s −1 ); HR, heart rate (bpm); Pa, aortic pressure (mm Hg); Pd, distal coronary pressure (mm Hg); VAR, variable arteriolar resistance; and VAR%, percentage variable arteriolar resistance. Impact of TAVI on Coronary Hemodynamics is thereby associated with an immediate improvement in the reserve vasodilatory capacity of the coronary microcirculation and CFR, in particular in patients without aortic regurgitation after TAVI.
Physiological and Pathological Alterations of the Coronary Circulation in Aortic Valve Stenosis
Advanced aortic valve stenosis leads to a compensatory increase in left ventricular mass to overcome the resistance induced by the outflow tract obstruction. 1 This increase in myocardial mass increases myocardial oxygen demand, whereas the same process simultaneously induces a counter-effective capillary rarefaction. 20 To maintain sufficient myocardial blood flow, coronary autoregulation is therefore expected to induce compensatory vasodilation of the coronary resistance vessels. 5, 6, 21, 22 This concurs with the results of the present study, documenting a decrease in baseline microvascular resistance, thus an intrinsic compensatory vasodilation of the coronary resistance vessels, to accommodate resting myocardial blood flow. Aortic valve stenosis not only induces physiological alterations in resting, autoregulated, microvascular resistance associated with the increase in myocardial mass, but is also associated with a pathological increase in minimal microvascular resistance: both the abnormal loading conditions in aortic valve stenosis and the consequent increase in myocardial mass result in a pertinent increase in extravascular compression of the coronary microcirculation. Additionally, the increase in ventricular mass influences cardiac contraction, which results in a pathological reduction of diastolic perfusion time. As a result of these phenomena, minimal microvascular resistance is pathologically increased in patients with advanced aortic valve stenosis, resulting in an impairment of myocardial perfusion. Accordingly, in the present study, we document an increase in minimal microvascular resistance in patients with aortic valve stenosis as compared with patients without aortic valve stenosis or left ventricular hypertrophy, which was associated with a pertinently reduced hyperemic coronary flow, and hence contributed to an impairment in coronary flow reserve.
Overall, the compensatory alterations in myocardial structure and function in response to progressive aortic valve stenosis are associated with important dysfunction of the coronary microvasculature, which is expressed in all indices of microvascular function and coronary flow. Such coronary microvascular dysfunction is unequivocally associated with impaired clinical prognosis, 4, 11, [23] [24] [25] [26] and its reversal could therefore impart a particularly important prognostic value.
Effect of TAVI on Coronary Hemodynamics
Relief of aortic valve stenosis by TAVI induces an immediate decrease in ventricular hemodynamic load and is thereby expected to relieve, in part, the extravascular compression of the coronary microvasculature. [27] [28] [29] Accordingly, we documented that TAVI induces an immediate decrease in minimal microvascular resistance toward reference values as obtained in patients without aortic valve stenosis or myocardial hypertrophy. This observed reduction in minimal microvascular resistance was associated with an increase in hyperemic coronary flow, which was consequently responsible for an increase in the vasodilatory reserve of the microvasculature and coronary flow reserve. The hypothesis that ventricular loading is a major contributor to coronary microvascular dysfunction in AS is supported by the enhanced effect of TAVI on restoration of coronary flow reserve in patients with none or trivial to mild aortic regurgitation after TAVI. However, because resting coronary hemodynamics did not improve immediately Values are mean±SD. APV indicates average peak flow velocity (cm/s); bMR, baseline microvascular resistance (mm Hg·cm·s −1 ); CFR, coronary flow reserve; hMR, hyperemic microvascular resistance (mm Hg·cm·s −1 ); HR, heart rate (bpm); Pa, aortic pressure (mm Hg); Pd, distal coronary pressure (mm Hg); VAR, variable arteriolar resistance; and VAR%, percentage variable arteriolar resistance. flow velocity in patients with aortic stenosis before TAVI, after TAVI without postprocedural aortic regurgitation, and in the control group during baseline and hyperemic conditions. APV indicates average peak flow velocity; AS, aortic stenosis; and TAVI, transcatheter aortic valve implantation. Impact of TAVI on Coronary Hemodynamics after TAVI, the vasodilatory capacity of the coronary circulation in AS patients treated by TAVI remained impaired in comparison with control patients without aortic valve stenosis or ventricular hypertrophy. The finding that resting coronary hemodynamics remains equivalent pre-and post-TAVI is consistent with previous observations by Davies et al, 6 as well as Camuglia et al, 30 which conceivably results from the effects of coronary autoregulation. The difference in pre-and post-TAVI baseline microvascular resistance and coronary flow in comparison with patients without AS likely originates from the fact that the lower magnitude of baseline microvascular resistance and higher magnitude of baseline coronary flow documented in AS patients reflect compensatory microvascular vasodilation in response to the increase in left ventricular mass and capillary rarefaction secondary to longstanding AS, which is not altered immediately after TAVI, but may regress and remodel over time. Hence, full restoration of coronary hemodynamics after TAVI likely requires longer follow-up studies.
It is important to note, however, that the changes in hyperemic coronary hemodynamics after TAVI were observed in the presence of a slight, though statistically significant, increase in heart rate post-TAVI. Such an increase in heart rate may affect coronary flow reserve because an increased myocardial demand is associated with exhaustion of the vasodilatory capacity of the coronary circulation and, hence, CFR. As a result, the documented improvement in coronary flow reserve across the study population may well underestimate true relief of extravascular compression, which might be partly obscured by concomitant transient changes in hemodynamics.
Effect of TAVI on Stenosis Physiology
FFR, the mean distal coronary to mean aortic pressure ratio during hyperemia, is currently recommended to guide revascularization in coronary stenosis of equivocal angiographic severity. This is of clinical importance in the setting of aortic valve stenosis because concomitant coronary artery disease is prevalent in up 70% of TAVI patients. 16, 31, 32 However, it is important to acknowledge that the pressure drop across a stenosis, and hence FFR, is determined by the magnitude of trans-stenotic flow during hyperemia, which in turn depends on hyperemic microvascular resistance. 33 Because TAVI decreases hyperemic microvascular resistance and thereby increases hyperemic flow, as documented in the present study, TAVI is likely to influence stenosis assessment using FFR. Accordingly, we document that FFR decreased significantly after TAVI, even in angiographically unobstructed reference coronary arteries where an increase in hyperemic transvascular flow induces a mild pressure loss because of the limited flow separation losses that occur in the absence of focal stenosis. 34 This finding, although hypothesis-generating, therefore suggests that FFR assessment of coronary stenoses in aortic valve stenosis patients could underestimate functional stenosis severity. This warrants further evaluation in patients with aortic valve stenosis and obstructed coronary arteries where flow separation losses dominate to document its potential effect on clinical decision-making. Interestingly, because basal flow before TAVI is similar to basal flow post-TAVI, basal conditions might provide a more favorable condition for the evaluation of epicardial disease severity in the clinical setting of aortic valve stenosis. 35, 36 
Limitations
The present study involves patients with symptomatic aortic valve stenosis whom underwent TAVI based on international recommendations. As such, our results are applicable only to those patients with advanced aortic valve stenosis. Moreover, aortic valve stenosis patients were significantly older and less likely to be male as compared with patients without aortic valve stenosis; patient populations where microvascular dysfunction is known to be more prevalent. Hence, part of the remaining microvascular dysfunction between aortic valve stenosis patients and the control group could be governed by factors not associated with valvular stenosis itself.
Because the intravenous administration of adenosine was precluded by the clinical setting of TAVI, adenosine was administered intracoronary in a conservative dose. Although microvascular resistance in patients with aortic stenosis before TAVI, after TAVI without postprocedural aortic regurgitation, and in the control group. AS indicates aortic stenosis; BMR, baseline microvascular resistance index; HMR, hyperemic microvascular resistance index; and TAVI, transcatheter aortic valve implantation. Impact of TAVI on Coronary Hemodynamics there is an on-going discussion regarding the optimal dose of adenosine, the dose used in the present study has been validated extensively for its diagnostic characteristics against intravenously administered adenosine 34, 37 and has shown to allow equivalent clinical benefit when used to determine FFR in clinical practice. 38 Meanwhile, in the present study, an equivalent dosing regimen was maintained across pre-and post-TAVI measurements, as well as among control cases to facilitate comparison between groups, strengthening the findings in the present article.
Optimally, calculation of microvascular resistance and FFR includes correction for right atrial pressure. 39, 40 Because high-fidelity right atrial pressure measurements were not routinely performed, the microvascular resistance indices and FFR were not corrected for right atrial pressure. As a sensitivity analysis, a fixed venous pressure of 5 mm Hg was used to correct both the microvascular resistance indices and FFR, which did not materially alter the findings and conclusions presented in the article (data not shown).
Simultaneous assessment of intracoronary pressure and flow velocity is dependent on operator experience with this specific armamentarium. Moreover, although a reliable Doppler signal in general is more difficult to obtain in comparison with coronary pressure, all patients in the present study were evaluated in a large tertiary referral hospital by operators with ample experience in Doppler flow velocity measurements.
At our institution, TAVI is routinely performed under local analgesia, which is in contrast to previous studies 18, 41 This state is more varied than general anesthesia, whereas differing levels of conscious sedation may be associated with alterations in sympathetic tone and microcirculatory regulation.
However, the majority of patients in this study received local analgesia (n=22). Within those that received conscious sedation, the dose of anesthetics administered was low and the level of conscious sedation remained unaltered throughout the procedure. Moreover, although TAVI procedures may introduce considerable variations in systemic hemodynamics, all patients remained hemodynamically stable during the measurements, and pre-and post-TAVI systemic hemodynamics remained similar. Alterations in anaesthetics and volume status during the procedure were trivial, and no interventions were required to support systemic hemodynamics during the procedure. Finally, the fact that the majority of patients did not receive any sedation has allowed a robust comparison of coronary hemodynamics between TAVI and control patients, whom did not receive sedatives, strengthening the conclusions presented in this article.
Conclusions
Aortic stenosis induces both physiological and pathophysiological alterations in the coronary microvasculature in response to cardiac outflow tract obstruction. As a result, the reserve vasodilatory capacity of the coronary circulation is reduced in patients with AS. TAVI immediately improves ventricular hemodynamics and partly relieves a pathological increase in minimal microvascular resistance. TAVI is thereby associated with an improvement in coronary vasodilatory reserve. In contrast, physiological changes in autoregulatory microvascular tone in response to an increase in ventricular mass remain unaltered immediately after TAVI and conceivably exhibit gradual regression requiring longterm follow-up.
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